erlotinib hydrochloride has been researched along with thiazolidines in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (thiazolidines) | Trials (thiazolidines) | Recent Studies (post-2010) (thiazolidines) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 3,544 | 160 | 1,407 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cha, PH; Cho, J; Cho, YH; Choi, KY; Han, G; Kim, T; Lee, HY; Lee, J; Lee, SK; Min, DS; Park, J; Shin, WJ; Yang, JS | 1 |
1 other study(ies) available for erlotinib hydrochloride and thiazolidines
| Article | Year |
|---|---|
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Topics: Animals; beta Catenin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Protein Kinase Inhibitors; Protein Stability; Proto-Oncogene Proteins p21(ras); ras Proteins; Thiazolidines | 2019 |